Circulating biomarkers in familial cerebral cavernous malformation.

"Declaration of interests B.B is inventor of patents on PTX3 and obtains royalties on PTX3-related reagents. N.B. serves on Advisory Board and Speakers Bureau for Celgene and Janssen, and on Speakers Bureau for Takeda, Amgen."

"This work was funded by 10.13039/501100003197Italian Medicines Agency (AIFA-2016-023645933). Other funding contributed to the project: Associazione Italiana per la Ricerca sul Cancro AIRC 5 × 1000 call ‘Metastatic disease: the key unmet need in oncology’ to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture Airc), ERC (project EC-ERC-VEPC contract 74292), the Leducq Transatlantic Network of Excellence “21CVD03–ReVAMP”, the 10.13039/501100004359Swedish Research Council (Contract No. 2013-09279 and Contract No. 2021-01919)."

"The Treat_CCM trial is registered with EudraCT, 2017-003595-30, and ClinicalTrials.gov, NCT03589014. Written informed consent was obtained from all participants and the study was approved by local research ethics committees for each study site in accordance with the Declaration of Helsinki. The study was approved by AIFA (Agenzia Italiana del Farmaco, AIFA/SC/P/19831). The Treat_CCM trial is registered at EudraCT (2017-003595-30) and ClinicalTrials.gov (NCT03589014) and has been closed by December 2021."